The association between serum uric acid and diabetic complications in patients with type 2 diabetes mellitus by gender: a cross-sectional study

Yimeng Hu¹, Qinge Li², Rui Min², Yingfeng Deng³, Yancheng Xu² and Ling Gao¹

¹Department of Endocrinology & Metabolism, Renmin Hospital of Wuhan University, Wu Han, Hu Bei, China
²Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China
³Department of Internal Medicine, University of Texas Southwestern Medical Center, TX, USA

ABSTRACT

Background. The relationship between serum uric acid (SUA) and several diabetic complications or co-morbidities remains a matter of debate. The study aims to explore the association between SUA levels and the prevalence of non-alcoholic fatty liver disease (NAFLD), diabetic retinopathy (DR), diabetic nephropathy (DN) and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM).

Methods. A total of 2,809 participants (1,784 males and 1,025 females) were included in this cross-sectional study. Clinical characteristics and the prevalence of each of the four diseases were analyzed based on gender-specific quartiles of SUA levels. The Pearson correlation analysis and linear-regression analysis were used to access the correlation between SUA levels and clinical characteristics. Furthermore, a binary logistic regression analysis was carried out to determine whether SUA was an independent risk factor for each of the four complications.

Results. SUA levels were positively correlated to BMI, BUN, Scr and TG, but negatively associated with eGFR, HDL, FBG, 2h-PG and HbA1c% for the patients with T2DM. The prevalence of NAFLD and DN, but not DR or DPN, were increased with SUA levels from the first to the fourth quartile. Binary logistic regression further disclosed that SUA was an independent risk factor for NAFLD (ORs Male = 1.002, *P = 0.0013; ORs Female = 1.002, *P = 0.015) and DN (ORs Male = 1.006, *P < 0.001; ORs Female = 1.005, *P < 0.001), but not for DR and DPN. After adjustment for the confounders, SUA levels were significantly associated with NAFLD within the 3rd (ORs = 1.829, P = 0.004) and 4th quartile (ORs = 2.064, P = 0.001) for women, but not independently associated with SUA for man. On the other hand, our results revealed increased prevalence of DN for SUA quartile 2 (ORs = 3.643, P = 0.039), quartile 3 (ORs = 3.967, P = 0.024) and quartile 4 (ORs = 9.133, P < 0.001) in men; however, SUA quartiles were significantly associated with DN only for quartile 4 (ORs = 4.083, P = 0.042) in women

Conclusion. For patients with T2DM, elevated SUA concentration is an independent risk factor for the prevalence of NAFLD and DN after adjustment for other indicators, but not DR or DPN.

Subjects Diabetes and Endocrinology, Epidemiology, Hematology
Keywords Serum uric acid, Non-alcoholic fatty liver disease, Diabetic retinopathy, Diabetic nephropathy, Diabetic peripheral neuropathy

How to cite this article Hu Y, Li Q, Min R, Deng Y, Xu Y, Gao L. 2021. The association between serum uric acid and diabetic complications in patients with type 2 diabetes mellitus by gender: a cross-sectional study. PeerJ 9:e10691 http://doi.org/10.7717/peerj.10691
INTRODUCTION

Type 2 diabetes mellitus (T2DM), a metabolic disorder, is associated with various complications and co-morbidities that result in cardiovascular diseases, renal failure, blindness and neuropathy (Peterson & Hart, 2016). It is the long-term complications that account for the majority of mortality in patients with T2DM (IDF, 2019). It is therefore critical to identify a clinical biomarker which can be used for early detection and management of the development of diabetic complications and co-morbidities.

Uric acid is a product of purine degradation. Elevated uric acid causes a series of pathophysiological changes through inflammation, oxidative stress and activation of the renin-aldosterone-angiotensin system (RAAS), which subsequently promotes the initiation and progression of multiple diseases including metabolic syndrome (Xiong, Liu & Xu, 2019). Recently, serum uric acid (SUA) has been regarded as a risk factor for T2DM (Kodama et al., 2009) since hyperuricemia stimulates insulin secretion and aggravates insulin resistance (Hu et al., 2018; Zhong et al., 2019). A clinical study from 8,678 patients with gout reports that uric acid-lowering therapy improves insulin resistance and reduces the incidence of T2DM (Niu et al., 2018). However, a meta-analysis included six trials with 455 patients suggests that uric acid-lowering therapy with allopurinol may be effective at reducing glycemia, but such an improvement does not observed in patients with diabetes (Chen et al., 2020), suggesting that the significance of uric acid to T2DM might not be restricted to the incidence. It is therefore suspected that elevated SUA has some impact on the development and progression of complications associated with T2DM. Indeed, the relationship between SUA and various diabetic complications remains a matter of debate. Whereas longitudinal analyses demonstrated a unidirectional relationship from hyperuricemia to NAFLD incidence and lowering SUA levels may prevent subsequent NAFLD during the follow-up in non-T2DM population (Ma et al., 2020), a cross-sectional study have disclosed that SUA is not independently associated with NAFLD in T2DM after rigorous adjustment for additional metabolic parameters (Xu et al., 2019). Therefore, the relationship between NAFLD and hyperuricemia is debatable. Similarly, multiple lines of epidemiologic evidences have supported a role of SUA in the development of diabetic retinopathy (DR) in both T1DM and T2DM (Bjornstad et al., 2014; Liang et al., 2016); however, some studies found that high SUA levels were not associated with increased risk of DR in patients with T2DM (Xia et al., 2020). Diabetic nephropathy (DN), another microvascular complication of T2DM, is becoming a dominant factor leading to chronic kidney diseases (CKD) and renal transplantation. Numerous clinical studies have suggested that SUA is not only an independent risk factor for early renal disease, but also a driving force for the progression of renal dysfunction. Bjornstad and colleagues reports that during a 5.7-years follow-up period, higher baseline SUA is independently associated with increased risk for elevated urinary albumin excretion and reduced estimated glomerular filtration rate (eGFR) in obese adolescents with T2DM (Bjornstad et al., 2019). However, a cohort study of 3895 individuals with T1DM in Finland shows that baseline SUA is not independently associated with progression of DN despite being independently associated with the decline in eGFR, suggesting that increased SUA level is merely an outcome of
kidney damage (Ahola et al., 2017). In summary, it remains inconclusive whether SUA can be used as a diagnosis biomarker for diabetic complications and co-morbidities due to the controversy findings from animal and clinical studies.

Here we designed a cross-sectional study to examine whether SUA levels in T2DM are influenced by age, gender, body mass index (BMI), serum lipid, renal function and other characteristics. Meanwhile, we explored whether SUA is associated with the prevalence of diabetic complications or co-morbidities (including NAFLD, DR, DN and DPN) in T2DM with a goal to determine the independent risk factors for each of the four diseases. To illustrate the difference in the pathophysiology between males and females, all the aforementioned analyses were further conducted separately by gender.

**MATERIALS AND METHODS**

**Subjects**

The cross-sectional study enrolled patients with T2DM (20~85 y), who were hospitalized in the Department of Endocrinology, Zhongnan Hospital of Wuhan University, China, between June 2010 and April 2019. Based on plasma glucose criteria, T2DM was diagnosed by fasting blood glucose (FBG) ≥ 7.0 mmol/L or 2 h plasma glucose (2 h PG) >11.1 mmol/L during a 75 g oral glucose tolerance test (ADA, 2019). Patients with thyroid disease, Cushing syndrome, pheochromocytoma, malignant tumors, pregnancy, drinking history and those who were under uric acid-lowering, anti-hypertensive agents and lipid-lowering therapies were excluded. Finally, a total of 2,809 subjects (1,784 men and 1,025 women) were included in this retrospective study (Fig. 1). All the subjects received a low-sugar and low-fat diet and avoided excessive purine intake after their admission to the hospital. The study protocol has been approved by the Human Ethics Committee of Zhongnan Hospital, and all the participants had signed written informed consent (Ethical Application Ref: 2016019).

**Diagnose of diabetic complications or co-morbidities**

**Non-alcohol fatty liver disease (NAFLD)**

Although pathologic examinations of liver biopsies are the gold standard for the diagnosis of NAFLD, it is impossible to obtain liver tissue from every participant. Therefore, the diagnosis criteria were as the following (Fan et al., 2011): (a). Intake of alcohol <140 g/week for males and 70 g/week for females in the past 12 months. (b). Results of liver ultrasonic examination. (c). Specific diseases that lead to steatosis can be excluded.

**Diabetic retinopathy (DR)**

DR is usually classified as non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) with the former as the most common type of DR. The diagnosis of DR is by the lesions detected by ophthalmoscope examination which include microaneurysms, hemorrhages, soft exudates, hard exudates, neovascularization, and laser photocoagulation scars (Li et al., 2014). The examination was conducted at the Department of Ophthalmology and the images were interpreted by experienced and skilled ophthalmologists.
Figure 1  Flowchart of selection of study population.

Diabetic nephropathy (DN)

Early diagnosis of DN can be done by screening for albuminuria, or glomerular filtration rate (GFR) (Komenda et al., 2014). DN is diagnosed when urinary albumin excretion is more than 30 mg per 24 h in consecutive sterile urine specimens or eGFR<60 mL/min per 1.73 m² (Ahmad et al., 2019). The value of eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Levey et al., 2009). For males, eGFR = 141 × (Scr/0.9)−0.411 × (0.993)agee when Scr ≤ 0.9 mg/dL, while eGFR = 141 × (Scr/0.9)−1.209 × (0.993)agee when Scr >0.9 mg/dL. For females, when eGFR = 144× (Scr/0.9)−0.329× (0.993)agee when Scr ≤ 0.7 mg/dL, while eGFR = 141× (Scr/0.9)−1.209× (0.993)agee when Scr >0.7 mg/dL.

CKD is classified to 5 stages by eGFR categories (Hasegawa et al., 2019): stage 1 (eGFR ≥ 90), stage 2 (60<eGFR ≤ 89), stage 3 (30<eGFR ≤ 59), stage 4 (15<eGFR ≤ 29) and stage 5 (eGFR ≤ 15). When CKD has advanced to stage 3, the diagnosis of DN for T2DM patients will be confirmed.
**Diabetic peripheral neuropathy (DPN)**

DPN can be comprehensively evaluated with sensory and motor nerve conduction tests. Moreover, electrophysiological assessment has been used as an auxiliary examination to assess the conduction speed and latent-period of nerves. Clinically, the diagnosis of DPN includes the following aspects (Shabeeb et al., 2018): a. symptoms of nerve damage, including numbness, tingling, or pain in the extremities; b. physical examination, including muscle strength, reflexes, sensitivity to position changes, temperature, light touch and foot exam; c. report of macro electromyography that should be operated by neurological physician.

**Physical examination and laboratory measurements**

All participants were required to take an interview to collect information about age, duration of T2DM, family disease history, alcohol consumption, smoking, and past medical conditions (Hu et al., 2018). When the patient was admitted to the hospital, a well-trained nurse would perform a simple physical examination, including height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP). BMI was calculated as weight in kilograms divided by the height in meters squared (kg/m\(^2\)). In addition, blood samples were collected from patients’ antecubital vein at overnight fasting and 2 h after a 75 g oral glucose load. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), free fatty acid (FFA), blood urea nitrogen (BUN), serum creatinine (Scr), and serum uric acid (SUA), fasting blood glucose (FBG) and postprandial blood glucose (2h-PG) were measured on ADVIA® 2400 Clinical Chemistry System (Siemens) according to the manufacturer’s instructions. HbA1c% was measured by enzymatic method using whole blood. To detect the levels of urinary albumin (Alb), patients were asked to collect urine for 24 h on the second day after admission.

**Statistical analysis**

In this study, we used the multiple imputation method to impute the missing values by MI procedure in SAS 9.4 software (SAS Institute, Cary, NC). Sex-specific quartiles of SUA (\(\mu\)mol/L) were set up in male/female respectively: first quartile (Q1): <269.0/220.6 \(\mu\)mol/L, second quartile (Q2): 269.0–326.0/220.6–273.9 \(\mu\)mol/L, third quartile (Q3): 326.0–390.7/273.9–338.9 \(\mu\)mol/L, and fourth quartile (Q4): \(\geq\) 390.7/338.9 \(\mu\)mol/L. All continuous variables were presented as the mean ± SD or median with interquartile range (IQR). One-way ANOVA was used to compare intergroup difference. Categorical variables were displayed as a number (proportion), and the intergroup comparison was performed by the chi-square test (\(\chi^2\)). The Pearson correlation analysis and linear-regression analysis were used to determine the correlation between SUA levels and age, duration of T2DM, BMI, SBP, DBP, TC, TG, HDL-c, LDL-c, FFA, BUN, Scr, eGFR, Alb, FBG, 2h-PG and HbA1c%. Binary logistic regression analysis was conducted to identify independent risk factors associated with the prevalence of the four diseases. We further performed logistical regression analysis using SUA quartile 1 as the reference group with adjustment for potential confounders to evaluate the specific association between the prevalence of
diseases with SUA quartiles. The results were presented as odds ratios (ORs) and 95% confidence intervals (95% CIs). The results of multicollinearity test and goodness of fit test (Hosmer-Lemeshow) for each model were displayed in Table S1. A two-tailed \( p < 0.05 \) was considered statistically significant. All statistical analyses were conducted using SPSS software (version 21.0; SPSS, Chicago, IL, USA) and GraphPad Prism (version 8.0; GraphPad Software Inc., San Diego, CA, USA).

**RESULTS**

**Gender-specific clinical characteristics of participants according to SUA levels**

Table 1 displayed the demographic and clinical characteristics of 2,809 participants including 1,784 men and 1,025 women in the four SUA quartiles, respectively. In males, BMI \((P < 0.001)\), SBP \((P = 0.001)\), BUN \((P < 0.001)\), Scr \((P < 0.001)\), TC \((P = 0.006)\) and TG \((P < 0.001)\) had a significantly increasing trend across the SUA quartiles. In contrast, eGFR \((P < 0.001)\), HDL \((P < 0.001)\), LDL \((P = 0.021)\), FBG \((P < 0.001)\), 2h-PG \((P < 0.001)\) and HbA1c% \((P < 0.001)\) were lower in the quartile 4 than quartile 1. Age \((P = 0.067)\), duration of T2DM \((P = 0.84)\) and DBP \((P = 0.127)\), however, showed no statistical difference across the SUA quartiles in male. Different from the male, female participants showed no significant difference in SBP \((P = 0.15)\), DBP \((P = 0.48)\), TC \((P = 0.63)\) and FFA \((P = 0.22)\) across the four quartiles. Whereas age \((P = 0.001)\), BMI \((P = 0.001)\), BUN \((P < 0.001)\), Scr \((P < 0.001)\), Alb \((P = 0.005)\) and TG \((P < 0.001)\) showed a trend of increasing across the SUA quartiles in the female, eGFR \((P < 0.001)\), HDL-c \((P < 0.001)\), LDL-c \((P = 0.009)\), FBG \((P < 0.001)\), 2h-PG \((P < 0.001)\) and HbA1c% \((P < 0.001)\) were significantly decreased with ascending SUA quartiles.

**Correlations between SUA and clinical characteristics by gender**

As demonstrated in Fig. 2, SUA levels were positively correlated to BMI \((r = 0.24, P < 0.0001; r = 0.20, P < 0.0001)\), BUN \((r = 0.15, P < 0.0001; r = 0.27, P < 0.0001)\), Scr \((r = 0.23, P < 0.0001; r = 0.35, P < 0.0001)\) and TG \((r = 0.22, P < 0.000; r = 0.20, P < 0.0001)\) in male and female, respectively. Meanwhile, SUA levels were negatively correlated to eGFR \((r = -0.18, P < 0.0001; r = -0.33, P < 0.0001)\), HDL \((r = -0.19, P < 0.0001; r = -0.25, P < 0.0001)\), FBG \((r = -0.11, P < 0.0001; r = -0.10, P = 0.002)\), 2h-PG \((r = -0.16, P < 0.0001; r = -0.13, P < 0.0001)\) and HbA1c% \((r = 0.14, P < 0.000; r = -0.17, P < 0.0001)\) in male and female, respectively. The correlation of SUA with age, SBP, and TC showed some differences between men and women. In male, SUA showed a reducing tendency with incremental age in males \((r = -0.07, P = 0.02)\), while in female, SUA showed a positive association with age \((r = 0.11, P = 0.0007)\). In male, SUA was positively correlated to SBP and TC \((r = 0.07, P = 0.02; r = 0.08, P = 0.0007)\), while in female, no correlation was observed \((r = 0.03, P = 0.33; r = 0.001, P = 0.97)\). In summary, HDL, BMI, BUN, Scr, eGFR and TG showed strong correlation with SUA, among which Scr seems to have the strongest impact on SUA for both genders.
| Table 1  Clinical characteristics of all participants according to quartiles of serum uric acid levels. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Overall         | Quartile 1      | Quartile 2      | Quartile 3      | Quartile 4      | P for trend     |
| Male Characteristics             | n = 1,784       | n = 445         | n = 447         | n = 446         | n = 446         |                 |
| serum uric acid range (µmol/L)   |                 |                 |                 |                 |                 |                 |
| age (year)                       | 54.2 ± 12.1     | 55.5 ± 11.4     | 53.4 ± 11.2     | 54.0 ± 12.7     | 53.8 ± 12.8     | 0.067           |
| duration (years)                 | 5.0(1.0,10.0)   | 5(1.0,10.0)     | 5.0(1.0,10.0)   | 5.0(1.0,10.0)   | 5.0(1.0,10.0)   | 0.84            |
| BMI (kg/m²)                      | 25.3 ± 3.3      | 24.3 ± 3.3      | 25.3 ± 3.3      | 25.7 ± 3.3      | 26.3 ± 3.3      | <0.001*         |
| SBP (mmHg)                       | 130.1 ± 17.2    | 128.0 ± 16.7    | 129.3 ± 17.6    | 131.6 ± 16.5    | 131.3 ± 17.8    | 0.001*          |
| DBP (mmHg)                       | 78.4 ± 10.8     | 77.6 ± 10.0     | 78.6 ± 11.2     | 78.3 ± 10.1     | 79.2 ± 11.7     | 0.127           |
| BUN (mmol/L)                     | 5.7 ± 1.6       | 5.4 ± 1.5       | 5.5 ± 1.4       | 5.8 ± 1.6       | 6 ± 1.9         | <0.001*         |
| Scr (µmol/L)                     | 71.2(62.6,82.3) | 65.7(58.8,74.0) | 69(61.5,79.9)   | 72.2(64.2,83.0) | 78.2(67.8,90.1) | <0.001*         |
| eGFR (mL/min/1.73m²)             | 107.3(91.3,118.7)| 91(99.4,119.8)| 109.4(94.2,120.6)| 107.2(89.4,118.7)| 100.1(80.0,113.6)| <0.001*         |
| A (mg/24h)                       | 12.5(5.9,22.7)  | 11.8(5.7,22.7)  | 11.6(5.8,22.7)  | 13.7(6.5,22.7)  | 13.0(5.9,22.7)  | 0.089           |
| TC (mmol/L)                      | 4.7 ± 1.2       | 4.6 ± 1.0       | 4.8 ± 1.1       | 4.7 ± 1.1       | 4.8 ± 1.1       | 0.006*          |
| TG (mmol/L)                      | 1.8(1.2,2.9)    | 1.4(1.0,2.1)    | 1.7(1.2,2.9)    | 1.8(1.2,3.0)    | 2.2(1.4,3.7)    | <0.001*         |
| HDL-c (mmol/L)                   | 0.99 ± 0.3      | 1.1 ± 0.3       | 1.0 ± 0.3       | 0.99 ± 0.3      | 0.93 ± 0.2      | <0.001*         |
| LDL-c (mmol/L)                   | 2.8 ± 0.9       | 2.9 ± 0.8       | 2.9 ± 0.9       | 2.8 ± 0.9       | 2.7 ± 0.9       | 0.021*          |
| FFA (µmol/L)                     | 552.3(404.7,635.8)| 508.6(391.8,621.2)| 522.4(399.9,631.2)| 535.5(407.0,649.7)| 533.4(413.9,649.8)| 0.106           |
| FBG (mmol/L)                     | 8.4(6.3,11.3)   | 9.3(6.8,12.1)   | 8.4(6.3,11.9)   | 8.0(6.2,10.9)   | 7.8(6.0,10.4)   | <0.001*         |
| PBG (mmol/L)                     | 18.1 ± 5.4      | 19.4 ± 5.4      | 18.4 ± 5.3      | 17.7 ± 5.1      | 16.9 ± 5.3      | <0.001*         |
| HbA1c (%)                        | 8.5(7.0,10.3)   | 9.3(7.6,11.1)   | 8.6(7.1,10.4)   | 8.3(7.0,9.9)    | 7.8(6.7,9.6)    | <0.001*         |
| Female Characteristics           | n = 1,025       | n = 255         | n = 258         | n = 256         | n = 256         |                 |
| serum uric acid range (µmol/L)   | <220.6          | 220.6-273.9     | 273.9-338.9     | >390.7          |                 |                 |
| age (year)                       | 60.1 ± 11.3     | 58.6 ± 10.7     | 59.6 ± 10.1     | 60.3 ± 10.9     | 61.8 ± 13.2     | 0.001*          |
| duration (years)                 | 6.0(2.0,10.0)   | 5.0(1.0,10.0)   | 6.0(1.0,10.0)   | 7.0(2.3,10.0)   | 7.0(2.0,13.0)   | 0.001*          |
| BMI (kg/m²)                      | 24.9 ± 3.6      | 24.0 ± 3.2      | 24.8 ± 3.9      | 25.1 ± 3.4      | 25.8 ± 3.8      | <0.001*         |
| SBP (mmHg)                       | 131.3 ± 18.6    | 129.3 ± 18.1    | 132.4 ± 19.4    | 131.5 ± 19.4    | 132.1 ± 17.6    | 0.15            |
| DBP (mmHg)                       | 74.7 ± 10.6     | 74.7 ± 10.6     | 75.0 ± 10.5     | 75.4 ± 9.5      | 73.9 ± 11.5     | 0.48            |
| BUN (mmol/L)                     | 5.3 ± 1.8       | 4.9 ± 1.3       | 5.0 ± 1.4       | 5.3 ± 1.4       | 6.0 ± 2.6       | <0.001*         |
| Scr (µmol/L)                     | 55.0(47.2,64.0) | 50.4(44.1,56.9) | 52.8(46.0,61.0) | 56.3(49.0,65.2) | 62.2(52.5,76)   | <0.001*         |
| eGFR (mL/min/1.73 m²)            | 97.5(87.4,107.5)| 101.8(93.4,111.0)| 99.4(91.7,108.6)| 96.2(84.8,104.3)| 90.1(70.0,102.5)| <0.001*         |
| ALB (mg/24h)                     | 11.7(5.7,21.8)  | 9.8(5.1,21.8)   | 11.0(5.1,21.8)  | 11.6(5.7,21.8)  | 14.8(6.6,22.1)  | 0.005*          |

(continued on next page)
### Table 1 (continued)

|                       | Overall       | Quartile 1    | Quartile 2    | Quartile 3    | Quartile 4    | P for trend |
|-----------------------|---------------|---------------|---------------|---------------|---------------|-------------|
| TC (mmol/L)           | 4.8 ± 1.2     | 4.8 ± 1.1     | 4.8 ± 1.2     | 4.8 ± 1.3     | 4.7 ± 1.3     | 0.63        |
| TG (mmol/L)           | 1.7 (1.2, 2.4)| 1.4 (1.0, 1.4)| 1.6 (1.1, 2.3)| 1.9 (1.3, 2.8)| 2.0 (1.3, 2.9)| <0.001 *   |
| HDL-c (mmol/L)        | 1.1 ± 0.3     | 1.2 ± 0.3     | 1.1 ± 0.3     | 1.1 ± 0.3     | 1.0 ± 0.3     | <0.001 *   |
| LDL-c (mmol/L)        | 2.8 ± 1.0     | 3.0 ± 0.9     | 2.9 ± 1.0     | 2.9 ± 1.1     | 2.7 ± 1.0     | 0.009 *    |
| FFA (µmol/L)          | 522.5 (400.7, 628.6) | 522.9 (393.9, 620.5) | 504.2 (387.6, 642.8) | 524.9 (406.2, 637.5) | 540.3 (416.9, 630.1) | 0.22       |
| FBG (mmol/L)          | 8.1 (6.0, 10.9)| 9.3 (6.6, 12.3)| 8.4 (5.7, 11.3)| 7.6 (5.7, 10.2)| 7.9 (6.2, 9.7) | <0.001 *   |
| 2h-PG (mmol/L)        | 18.4 ± 5.7    | 20.0 ± 5.7    | 18.6 ± 5.8    | 17.3 ± 5.3    | 17.6 ± 5.0    | <0.001 *   |
| HbA1c (%)             | 8.3 (7.0, 10.1)| 9.1 (7.5, 11.1)| 8.2 (6.7, 10.3)| 8.0 (6.7, 9.6)| 7.8 (6.9, 9.4)| <0.001 *   |

**Notes.**

SUA, serum uric acid; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; ALB, urinary microalbumin; TC, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol; FFA, free fatty acid; FPG, fasting plasma glucose; 2h-PG, 2 h postprandial plasma glucose; HbA1c%, glycosylated hemoglobin.

Data are expressed as mean ± SD, number (percentage), and median (interquartile ranges). *P* for trend was used to test the linear variation trend between clinical characteristic and SUA quartiles.

*Represented that the difference was significant.
Figure 2 Correlation analysis between serum uric acid (SUA) with clinical characteristics by gender using Pearson correlation analysis and linear-regression analysis. (A, B) Correlation analysis between SUA and age in male (A) and female (B); (C, D) correlation analysis between SUA and BMI in male (A) and female; (E, F) correlation analysis between SUA and SBP in male (E) and female (F); (G, H) correlation analysis between SUA and Scr in male (I) and female (J); (K, L) correlation analysis between SUA and eGFR in male (K) and female (L); (M, N) correlation analysis between SUA and TC in male (M) and female (N); (O, P) correlation analysis between SUA and TG in male (O) and female (P); (Q, R) correlation analysis between SUA and HDL-c in male (Q) and female (R); (S, T) correlation analysis between SUA and 2h-PG in male (S) and female (T); (V, W) correlation analysis between SUA and 2h-PG in male (V) and female (W); (X, Y) correlation analysis between SUA and HbA1c% in male (X) and female (Y). r represents Pearson r value; an asterisk (*) represents $P < 0.05$ (two tailed).
Table 2 The prevalence of diabetic complications across SUA quartiles in participants by gender.

| Serum uric acid quartiles | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend |
|--------------------------|------------|------------|------------|------------|-------------|
| Male                     | n = 445    | n = 447    | n = 446    | n = 446    |             |
| NAFLD (%)                | 34.6       | 43.6       | 46.9       | 48.7       | <0.05*      |
| Diabetic retinopathy (%) | 7.9        | 8.5        | 9          | 6.3        | 0.451       |
| Diabetic peripheral neuropathy (%) | 10.1           | 7.9        | 9.0        | 9.4        | <0.05*      |
| Female                   | n = 255    | n = 258    | n = 256    | n = 256    |             |
| NAFLD (%)                | 33.3       | 43.4       | 50         | 52         | <0.001*     |
| Diabetic retinopathy (%) | 1.2        | 0.8        | 3.9        | 5.4        | 0.168       |
| Diabetic peripheral neuropathy (%) | 9           | 8.6        | 12.1       | 9.1        | 0.525       |
| Diabetic nephropathy (%)  | 11.8       | 11.3       | 11.7       | 12.6       | <0.01*      |
| CKD1 (%)                 | 87.1       | 86.7       | 78.1       | 66.5       | <0.001*     |
| CKD2 (%)                 | 10.6       | 10.2       | 17.6       | 20.5       | <0.002*     |
| CKD3 (%)                 | 0.8        | 0.8        | 1.6        | 9.4        | <0.003*     |
| CKD4 (%)                 | 0          | 0          | 0.4        | 1.2        | 0.22        |
| CKD5 (%)                 | 0          | 0          | 0          | 0          | /           |

**Notes.**

*P for trend was used to test the linear variation trend between each of the complications and SUA quartiles.

*The difference was significant.

**Association of SUA level with prevalence rate of diabetic complications**

The prevalence of NAFLD was significantly different across the SUA quartiles in both men and women (Table 2). From the first to the fourth quartile, the prevalence rate was 34.60%, 43.60%, 46.90% and 48.70% in male, and 32.20%, 43.30%, 50.00% and 51.60% in female, respectively. The results indicated that the prevalence of NAFLD increased with the progression of hyperuricemia. Similar to NAFLD, the prevalence of DN was significantly different across the SUA quartiles in both men and women. From the first to the fourth quartile, the prevalence rate was 0.9%, 2.7%, 5.2% and 9.4% in male, and 1.2%, 0.8%, 3.9% and 5.4% in female, respectively.

Based on eGFR value, we performed CKD grading for all the participants (Table 2) and found that the majority of T2DM patients were in CKD1 stage, suggesting that the deterioration of renal function is delayed in the current cohort which might be a result from glucose-lowering treatment. The proportion of CKD1 was decreased with SUA in both genders. From the first to the fourth SUA quartile, the proportion was 90.6%, 84.85, 81.4%, and 73.8% in male, and 87.1%, 86.7%, 78.1% and 66.5% in female, respectively. In contrast, the proportions of CKD2 and CKD3 were higher in the fourth quartile than the first quartile.
Table 3  Binary logistic regression analysis on related variables for the prevalence of diabetic complications in men.

|                | Odds Ratio | 95% CI       | P value |
|----------------|------------|--------------|---------|
| NAFLD          |            |              |         |
| BMI            | 1.196      | 1.154–1.239  | <0.001  |
| TG             | 1.145      | 1.055–1.242  | 0.001   |
| SUA            | 1.002      | 1.000–1.003  | 0.001   |
| DBP            | 1.015      | 1.003–1.027  | 0.018   |
| Diabetic retinopathy | 1.062  | 1.029–1.096  | <0.001  |
| Duration       |            |              |         |
| FFA            | 0.999      | 0.998–1.000  | 0.012   |
| BMI            | 1.067      | 1.008–1.131  | 0.026   |
| LDL            | 0.583      | 0.353–0.963  | 0.035   |
| Diabetic nephropathy |        |              |         |
| Age            | 1.098      | 1.065–1.132  | <0.001  |
| BUN            | 2.146      | 1.816–2.536  | <0.001  |
| SUA            | 1.006      | 1.003–1.009  | <0.001  |
| SBP            | 1.021      | 1.005–1.038  | 0.01    |
| Diabetic peripheral neuropathy | 1.124 | 1.046–1.208  | 0.0015  |
| FBG            |            |              |         |
| Duration       | 1.041      | 1.015–1.068  | 0.002   |
| HDL            | 2.163      | 1.192–3.924  | 0.011   |

Notes.
SUA, serum uric acid; BMI, body mass index; SBP, systolic blood pressure; BUN, blood urea nitrogen; HDL-c, high-density lipoprotein-cholesterol; FPG, fasting plasma glucose.

Participants without non-alcoholic fatty liver disease (NAFLD) / diabetic retinopathy (DR) / diabetic nephropathy (DN) / diabetic peripheral neuropathy (DPN) were defined as 0 and those with NAFLD/ DR/DN/DPN as 1. P-value derived binary logistic regression analysis. Only the variables whose $p < 0.05$ were shown in the table.

Different from NAFLD and DN, the prevalence rate of DR ($P = 0.45$) and DPN ($P = 0.25$) had no significant differences among the four groups for men and women. Taken together, our findings indicate that the association of SUA quartiles and the diabetic complications was similar in men and women.

Identification of independent risk factors for the four diabetic complications

To identify independent risk factors for the four diseases associated with T2DM, binary logistic regression analysis was performed for each one. The results for males and females were displayed in Tables 3 and 4.

For NAFLD, BMI (ORs = 1.196, $P < 0.001$; ORs = 1.201, $P < 0.001$), TG (ORs = 1.145, $P = 0.001$; ORs = 1.370, $P < 0.001$) and SUA (ORs = 1.002, $P = 0.001$; ORs = 1.002, $P = 0.015$) were the independent risk factors for both men and women. Besides, DBP (ORs = 1.015, $P = 0.018$) was a risk factor only for men, while LDL (ORs = 1.686, $P = 0.005$) was a risk factor only for women.

For DR, duration of T2DM was the common risk factor for both genders (ORs Male = 1.062, $P < 0.001$; ORs Female = 1.045, $P = 0.006$). In males, BMI (ORs = 1.067, $P = 0.026$)
Table 4  Binary logistic regression analysis on related variables for the prevalence of diabetic complications in women.

|                  | Odds Ratio | 95% CI       | P value |
|------------------|------------|--------------|---------|
| **NAFLD**        |            |              |         |
| BMI              | 1.192      | 1.43–1.244   | <0.001  |
| TG               | 1.436      | 1.226–1.682  | <0.001  |
| HDL              | 0.486      | 0.274–0.861  | 0.014   |
| SUA              | 1.003      | 1.001–1.004  | 0.005   |
| **Diabetic retinopathy** |          |              |         |
| Duration         | 1.045      | 1.011–1.079  | 0.010   |
| **Diabetic nephropathy** |      |              |         |
| Age              | 1.101      | 1.051–1.153  | <0.001  |
| BUN              | 2.103      | 1.715–2.579  | <0.001  |
| SUA              | 2.015      | 1.021–1.008  | 0.00    |
| **Diabetic peripheral neuropathy** |        |              |         |
| Duration         | 1.067      | 1.035–1.099  | <0.001  |

Notes.
SUA, serum uric acid; BMI, body mass index; SBP, systolic blood pressure; BUN, blood urea nitrogen; TG, triglycerides; HDL-c, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol.

P-value derived Binary logistic regression analysis. Only the variables whose p < 0.05 were shown in the table.

was a risk factor, whereas LDL (ORs = 0.583, P = 0.035) and FFA (ORs = 0.999, P = 0.012) were protect factors.

For DN, age (ORs = 1.098, P < 0.001; ORs = 1.101, P < 0.001), BUN (ORs = 2.146, P < 0.001; ORs = 2.103, P < 0.001), SBP (ORs = 1.021, P = 0.01; ORs = 1.022, P = 0.042) and SUA (ORs = 1.006, P < 0.001; ORs = 1.005, P = 0.005) were found as positive impact factors for men and women.

For DPN, only duration of T2DM (ORs_{Male} = 1.041, P = 0.002; ORs_{Female} = 1.067, P < 0.001) was a risk factor for both genders. Furthermore, FBG (ORs = 1.124, P = 0.002) and HDL (ORs = 2.163, P < 0.001) were independently associated with the prevalence of DPN in males.

The results of regression analysis suggested that SUA plays a role in promoting the prevalence of NAFLD and DN for patients with T2DM, however, the effect was not strong. Therefore, logistic regression analysis was performed using SUA quartile 1 as the reference group to explore further the specific effect of SUA on NAFLD and DN. As shown in Table 5, the crude ORs of NAFLD (95% CI) were 1.462 (1.116, 1.916), 1.666 (1.272, 2.182), and 1.791 (1.368, 2.344) from the second to the fourth quartile of SUA for male, and 1.618 (1.129, 2.320), 2.110 (1.473, 3.022), and 2.281 (1.593, 3.268) for female, respectively. Based on the adjusted model, the ORs of NAFLD (95% CI) were 1.260 (0.942, 1.684), 1.347 (0.999, 1.824), 1.292 (0.941, 1.774) from the Q2 to the Q4 SUA for males, however, the difference was no longer statistically significant. Different from male, the ORs after adjustment in female were 1.829 (1.217, 2.749) and 2.064 (1.331, 3.203) in the Q3 and Q4 SUA, indicating that the effect of SUA on the prevalence of NAFLD in female was stronger than male.
Table 5. Logistic regression analysis of the association between quartiles of SUA and the prevalence of NAFLD and DN with T2DM.

|        | Male                         | | Female                        | |
|--------|------------------------------|---|-------------------------------|---|
|        | N ORs (95% CI) | P value | N ORs (95% CI) | P value |
| NAFLD  |                |          |                |          |
| Model 1|                |          |                |          |
| Q1     | 455 – –        | –        | 255 – –        | –        |
| Q2     | 447 1.462 (1.116, 1.916) | 0.006*   | 258 1.618 (1.129, 2.320) | 0.006*   |
| Q3     | 446 1.666 (1.272, 2.182) | <0.001*  | 256 2.110 (1.473, 3.022) | <0.001*  |
| Q4     | 446 1.791 (1.368, 2.344) | <0.010*  | 256 2.281 (1.593, 3.268) | <0.001*  |
| Model 2|                |          |                |          |
| Q1     | 455 – –        | –        | 255 – –        | –        |
| Q2     | 447 1.260 (0.942, 1.684) | 0.106    | 258 1.467 (0.986, 2.182) | 0.059    |
| Q3     | 446 1.347 (0.999, 1.814) | 0.051    | 256 1.829 (1.217, 2.749) | 0.004    |
| Q4     | 446 1.292 (0.941, 1.774) | 0.113    | 256 2.064 (1.331, 3.203) | 0.001    |
| DN     |                |          |                |          |
| Model 1|                |          |                |          |
| Q1     | 455 – –        | –        | 255 – –        | –        |
| Q2     | 447 3.041 (0.973, 9.503) | 0.056    | 258 2.000 (0.495, 8.085) | 0.331    |
| Q3     | 446 5.995 (2.056, 17.479) | 0.001*  | 256 3.415 (0.929, 12.556) | 0.065    |
| Q4     | 446 11.462 (4.074, 32.242) | <0.001*  | 256 16.486 (2.039, 53.941) | <0.001*  |
| Model 2|                |          |                |          |
| Q1     | 455 – –        | –        | 255 – –        | –        |
| Q2     | 447 3.643 (1.067, 12.439) | 0.039    | 258 1.516 (0.332, 6.928) | 0.592    |
| Q3     | 446 3.967 (1.203, 13.083) | 0.024*  | 256 2.095 (0.426, 7.456) | 0.426    |
| Q4     | 446 9.133 (2,839, 29,373) | <0.001*  | 256 4.083 (1.035, 16.109) | 0.042*   |

Notes.

Quartiles based on serum uric acid levels: first quartile, <269 µmol/L (<P25); second quartile, 269-326 µmol/L (P25-P50); third quartile, 326–390.7 µmol/L (P50-P75); and fourth quartile, >390.7 µmol/L (>P75) (Males). Quartiles based on serum uric acid levels: first quartile, <220.6 µmol/L (<P25); second quartile, 220.6–273.9 µmol/L (P25-P50); third quartile, 273.9–338.9 µmol/L (P50-P75); and fourth quartile, >338.9 µmol/L (>P75) (Females).

Data are presented as odds ratio (95% confidence interval) compared with first quartile 1. Participants without non-alcoholic fatty liver disease (NAFLD) / diabetic nephropathy (DN) were defined as 0 and those with NAFLD/ DN as 1. Model 1 for NAFLD: unadjusted variables; Model 2 for NAFLD: adjusted for age, BMI, duration, SBP, DBP, BUN, Scr, Alb, eGFR, TC, TG, HDL-c, LDL-c, FFA, FBG, PBG and HbA1c. Model 1 for DN: unadjusted variables; Model 2 for DN: adjusted for age, BMI, duration, SBP, DBP, BUN, TC, TG, HDL-c, LDL-c, FFA, FBG, PBG and HbA1c.

*The difference was significant.

The crude ORs of DN (95% CI) were 3.041 (0.973, 9.503), 5.995 (2.056, 17.479), and 11.462 (4.074, 32.242) in male, and 2.0 (0.495, 8.085), 3.415 (0.929, 12.456), and 2.447 (1.478, 4.049) in female, respectively. Based on the adjusted model, the ORs of DN from Q2 to the Q4 SUA were 3.643 (1.067, 12.439), 3.967 (1.203, 13.083) and 9.133 (2.839, 29.373) in men, which were statistically significant. Nevertheless, the ORs of DN were significantly increased only for the Q4 SUA in women [4.083 (1.035, 16.109)], which implied the impact of SUA on the prevalence of DN in male was more powerful than female.
DISCUSSION

The current population-based study of T2DM presented data stratified according to SUA quartiles in a sex-specific manner. The analysis found that SUA levels were positively correlated with BMI, BUN, Scr and TG, and negatively correlated with eGFR, HDL, FBG, 2h-PG and HbA1c% in both genders. Given the fact that BUN, Scr, and eGFR are the parameters reflecting the ability of glomeruli clearance, it can be inferred that the elevation of SUA level in T2DM is mainly attributed to the decline of the kidney function in terms of UA clearance. However, it also suggested that hyperuricemia impaired glomerular filtration, which subsequently led to the changes of BUN, Scr, and eGFR levels. Nevertheless, a causal relationship of SUA and the development of hypertension has been shown regardless of baseline renal function (Turak et al., 2013), which suggests that a role of SUA on blood pressure is unrelated to renal clearance. In addition, SUA levels are increased with BMI, congruent with the findings that obesity might cause overproduction and underexcretion of UA (Matsuura et al., 1998). Moreover, it has been reported that lowering SUA by benzbramorone significantly attenuates FFA elevation and promotes adipose tissue bengia via AMPK activation, and subsequently reduces adiposity in mice, suggesting that increased UA contribute to the development of metabolic abnormalities in adipose tissue (Su et al., 2020b). It didn’t make sense that SUA was negatively corelated with FBG, 2h-PG and HbA1c% which reflected blood glucose levels, which was consistent with previous study (Xu et al., 2019). However, a meta-analysis of 12 cohort studies reveals a positive nonlinear relationship between SUA levels and impaired fasting glucose (Jia et al., 2013). One of the possible reasons for this phenomenon is that hyperuricemia could promote insulin secretion to compensate for insulin resistance in the short term (Hu et al., 2018). In addition, we couldn’t eliminate the effect of hypoglycemic agent in this study, which might result in the relationship. Interestingly, the positive correlation between SUA and SBP was only observed in males but not females in the current study. Patients with hypertension often suffer from hyperuricemia due to the obstruction of UA excretion, however, the incidence of cardiovascular events stills soared 3-5 times even when their blood pressure is under strict control (Franse et al., 2000). This observation indicates that hyperuricemia can be an independent risk factor of cardiovascular events rather than a mere result of hypertension and renal impairment. However, a longitudinal study based on 1,666 T2DM patients concludes that SUA is not related to the incidence of hypertension (Janghorbani et al., 2018), suggesting an ambiguous role of UA in those diseases.

In this study, the prevalence of NAFLD in patients with T2DM was found increased from the first to the fourth quartile of SUA. Many clinical researches have reported that elevated SUA levels are associated with higher prevalence and the severity of NAFLD (Darmawan, Hamijoyo & Hasan, 2017). However, very few studies have been conducted to evaluate the significance of SUA in NAFLD in patients with T2DM. The logistical regression models with rigorous adjustments for other risk factors indicate that SUA is a significant risk factor for NAFLD in female, but not in male. Notably, a similar finding has been reported in the non-diabetic population (Wu et al., 2015). Although the reason for this gender difference is still uncertain, sex hormones may play a role, especially that estrogen facilitates excretion.
of UA during the reproductive period (Borges et al., 2010; Lee, Kim & Kim, 2017). With respect to the mechanism for SUA-mediated pathophysiology of NAFLD, UA has been reported to induce hepatic steatosis by stimulating fat acid synthesis, which precipitates the generation of mitochondrial oxidative stress, endoplasmic reticulum stress and SREBP-1c excessive activation (Choi et al., 2014; Lanaspa et al., 2012b). On the other hand, UA activates oxidative stress-induced lipid peroxidation, DNA damage and inflammatory response, which eventually generates cellular damage (Yu et al., 2010). Hepatocytes that exposed to uric acid for the long term are inclined to develop mitochondrial dysfunction and increase de novo lipogenesis, which jointly contributes to the incidence of NAFLD (Lanaspa et al., 2012b). It is well known that activity of the AMP-activated kinase (AMPK) is reduced in hepatic steatosis. UA, can inhibit AMPK activity in human hepatocytes (Lanaspa et al., 2012a).

Mounting studies have demonstrated that elevated SUA is an independent risk factor for the incidence of DN (Hayashino et al., 2016; Zoppini et al., 2012). Our studies found a significant increase in DN prevalence across SUA quartiles among subjects, especially in men, which highlighted a significant role of SUA on the development of DN in patients with T2DM. In order to evaluate the role of SUA as a risk factor for end stage renal disease (ESRD), the distribution of CKD was compared across SUA quartiles. The proportion of CKD1 was decreased with SUA, and the proportion of CKD2 and CKD3 were increased with the elevation in SUA, suggesting that SUA was a risk factor for kidney failure. Indeed, a cohort study that followed 2,367 patients with T2DM for a mean of 4.6 years found that SUA > 6.3 mg/dL (374.85 µmol/L) was an independent risk factor for the progression of CKD (Chang et al., 2016). The SUA value used in their study is comparable to the threshold value used for DN diagnosis here (SUA\text{Male} > 390.7 and SUA\text{Female} > 338.9 µmol/L). Interestingly, in moderate non-diabetic CKD, SUA ≥ 9 mg/dl is associated with higher mortality. However, once progressing to severe non-DM CKD, SUA < 5 mg/dl is associated with higher mortality, which suggested extremely reduced SUA means malnutrition (Lee & Tsai, 2020).

It has been reported that UA can damage microvascular, a mechanism for the pathogenesis of DN. Specifically, hyperuricemia leads to reduced production of endogenous nitric oxide (NO) and the injury of endothelial cells, which increases the oxidative stress and inflammation at glomerulus (Rock, Kataoka & Lai, 2013). Evidence from animal and clinical studies showed that UA-mediated RAS activation also is a novel mechanism of UA-induced endothelial dysfunction, which is closely related to cardiovascular and kidney diseases, such as atherosclerosis or DN (Su et al., 2020a). Moreover, UA sodium deposited in the renal interstitium impairs renal tubular function. However, a recent double-blind trial failed to show the clinical benefits of serum urate reduction with allopurinol on kidney outcomes among patients with T1DM (Doria et al., 2020). The discrepancy in conclusions between this study with previous studies may be caused by the indirect predictive effect of SUA on kidney dysfunction, which can be ascribed to the association of SUA with other risk factors that are causally related to DN, such as insulin resistance (Wang et al., 2019).

In contrast to DN, neither DR nor DPN was found associated with SUA levels, which was consistent with the previous reports (Xia et al., 2020). On the contrary, a multicenter
cross-sectional study in Thailand concludes that SUA is independently associated with peripheral neuropathy in T2DM patients, and elevated SUA should be considered a risk factor for DPN in clinical practice (Kaewput et al., 2020). Two explanations are suggested for the controversial findings. Firstly, the prevalence of DR and DPN were less than 12% in the current sectional-study, far below the average levels which are 20.8% and 20% for DR and DPN respectively in Asian people (IDF, 2019). This phenomenon might be caused by relatively increased awareness of T2DM in China, so the most of in-hospital patients with less complicated conditions. Secondly, the sample size of this study is limited to obtain a positive result. Nevertheless, the values of eGFR in the DR and DPN groups were lower than non-DR and non-DPN groups in this study (Supplemental Tables), which was in agreement with the findings by Yamamoto M et al. They have reported that simultaneous assessment of proteinuria and eGFR is necessary for appropriate evaluation of risks of severe eye complications in patients with diabetes (Yamamoto et al., 2019). Potential mechanisms for the development of DR in accordance with renal dysfunction may lie in the microvascular damage induced by inflammation, vascular endothelial dysfunction, and advanced glycation end products (Sabanayagam et al., 2014).

There are several limitations in this study. Firstly, this cross-section study lacks the power to track the alterations of SUA levels longitudinally during the progression of the diseases, making it difficult to determine the causality of SUA for diabetic complications. Secondly, the prevalence of diabetic complications was relatively lower than the average incidence in Asia, which could have hindered the discovery of significant difference among groups. Lastly, several antidiabetic drugs, such as metformin and SGLT-2 inhibitors could have profound effects on uric acid homeostasis, which could lead to altered SUA levels. Nevertheless, this population-based analysis reveals a significant link of SUA and a spectrum of clinical characteristics associated with T2DM. What’s more, this study comprehensively accesses the association between SUA levels and each of the four diabetic complications in a gender-dependent manner, which highlights the importance of clinical monitoring, early detection and sex-specific intervention for SUA to prevent the development of diabetic complications and co-morbidities.

CONCLUSIONS

In summary, a positive correlation between SUA and prevalence of NAFLD/DN is observed in T2DM patients for both genders. The correlation is subjected to the influence of several confounders, such that after adjustment elevated SUA is still an independent risk factor for the prevalence of NAFLD for female when the SUA values fall in the Q3 and Q4. Although SUA quartiles are positively associated with the prevalence of DN for males, the association exists only when the SUA values fall in the Q4 for females.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the National Natural Science Foundation of China (No.81571376 and No.81170767). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81571376, 81170767.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Yimeng Hu performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Qinge Li performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Rui Min performed the experiments, prepared figures and/or tables, and approved the final draft.
• Yingfeng Deng and Yancheng Xu analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
• Ling Gao conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The study protocol has been approved by the Human Ethics Committee of Zhongnan Hospital (Ethical Application Ref: 2016019).

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available in the Supplementary Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10691#supplemental-information.

REFERENCES
ADA. 2019. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 42:S13–S28 DOI 10.2337/dc19-S002.
Ahmad I, Zelnick LR, Batacchi Z, Robinson N, Dighe A, Manski-Nankervis J-AE, Furler J, O’Neal DN, Little R, Trence D. 2019. Hypoglycemia in people with type 2 diabetes and CKD. Clinical Journal of the American Society of Nephrology 6:844–853 DOI 10.2215/CJN.11650918.

Ahola AJ, Sandholm N, Forsblom C, Harjutsalo V, Dahlström E, Groop PH. 2017. The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes. Kidney International 91:1178–1185 DOI 10.1016/j.kint.2016.11.025.

Bjornstad P, Laffel L, Lynch J, Ghormli LEl, Weinstock RS, Tollefsen SE, Nadeau KJ, Group TS. 2019. Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care 42:1120–1128 DOI 10.2337/dc18-2147.

Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, Snell-Bergeon JK. 2014. Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. Acta Diabetologica 51:783–791 DOI 10.1007/s00592-014-0611-1.

Borges RL, Ribeiro AB, Zanella MT, Batista MC. 2010. Uric acid as a factor in the metabolic syndrome. Current Hypertension Reports 12:113–119 DOI 10.1007/s11906-010-0099-8.

Chang YH, Lei CC, Lin KC, Chang DM, Hsieh CH, Lee YJ. 2016. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus—a 4.6-year cohort study. Diabetes/Metabolism Research and Reviews 32:557–564 DOI 10.1002/dmrr.2768.

Chen J, Ge J, Zha M, Miao JJ, Sun ZL, Yu JY. 2020. Effects of uric acid-lowering treatment on glycemia: a systematic review and meta-analysis. Frontiers in Endocrinology 11:577 DOI 10.3389/fendo.2020.00577.

Choi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES, Lee KY, Lee BH, Johnson RJ, Kang DH. 2014. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Laboratory Investigation 94:1114–1125 DOI 10.1038/labinvest.2014.98.

Darmawan G, Hamijoyo L, Hasan I. 2017. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Medica Indonesiana 49:136–147.

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P. 2020. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. The New England Journal of Medicine 382:2493–2503 DOI 10.1056/NEJMoai1916624.

Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. 2011. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). Journal of Digestive Diseases 12:38–44 DOI 10.1111/j.1751-2980.2010.00476.x.

Franse LV, Pahor M, Bari MDi, Shorr RI, Wan JY, Somes GW, Applegate WB. 2000. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension 18:1149–1154 DOI 10.1097/00004872-200018080-00021.
Hasegawa T, Sakamaki K, Koiwa F, Akizawa T, Hishida A. 2019. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study. Clinical and Experimental Nephrology 23:189–198 DOI 10.1007/s10157-018-1621.

Hayashino Y, Okamura S, Tsuji S, Ishii H. 2016. Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. Acta Diabetologica 53:599–607 DOI 10.1007/s00592-015-0825-x.

Hu Y, Liu J, Li H, Zhu H, Liu L, Yuan Y, Chen J, Wang Y, Hu X, Xu Y. 2018. The association between elevated serum uric acid levels and islet beta-cell function indexes in newly diagnosed type 2 diabetes mellitus: a cross-sectional study. PeerJ 6:e4515 DOI 10.7717/peerj.4515.

International Diabetes Federation. 2019. IDF diabetes atlas. 9th edition. http://www.diabetesatlas.org/.

Janghorbani M, Ghanbari H, Aminorroaya A, Amini M. 2018. Relationship between serum uric acid and incident hypertension in patients with type 2 diabetes. Review of Diabetic Studies 14:354–363 DOI 10.1900/rd.s.2017.14.354.

Jia Z, Zhang X, Kang S, Wu Y. 2013. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Research and Clinical Practice 101:88–96 DOI 10.1016/j.diabres.2013.03.026.

Kaewput W, Thongprayoon C, Rangsri R, Jindarat S, Narindrarangkura P, Bathini T, Mao MA, Cheungpasitporn W. 2020. The association between serum uric acid and peripheral neuropathy in patients with type 2 diabetes mellitus: a multicenter nationwide cross-sectional study. Korean Journal of Family Medicine 41:189–194 DOI 10.4082/kjfm.18.0205.

Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. 2009. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 32:1737–1742 DOI 10.2337/dc09-0288.

Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N. 2014. Cost-effectiveness of primary screening for CKD: a systematic review. American Journal of Kidney Diseases 63:789–797 DOI 10.1053/j.ajkd.2013.12.012.

Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, Hunter B, Andres-Hernando A, Ishimoto T, Sanchez-Lozada LG, Thomas J, Hodges RS, Mant CT, Johnson RJ. 2012a. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLOS ONE 7:e48801 DOI 10.1371/journal.pone.0048801.

Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Sautin YY, Johnson RJ. 2012b. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in
fructose-dependent and -independent fatty liver. *Journal of Biological Chemistry* 287:40732–40744 DOI 10.1074/jbc.M112.399899.

Lee CL, Tsai SF. 2020. Association between mortality and serum uric acid levels in non-diabetes-related chronic kidney disease: an analysis of the National Health and Nutrition Examination Survey, USA, 1999–2010. *Scientific Reports* 10:17585 DOI 10.1038/s41598-020-74747-w.

Lee SH, Kim KM, Kim KN. 2017. Combined effect of serum gamma-glutamyltransferase and uric acid on incidence of diabetes mellitus: a longitudinal study. *Medicine* 96:e6901 DOI 10.1097/MD.0000000000006901.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. 2009. A new equation to estimate glomerular filtration rate. *Annals of Internal Medicine* 150:604–612 DOI 10.7326/0003-4819-150-9-200905050-00006.

Li LX, Li MF, Lu JX, Jia LL, Zhang R, Zhao CC, Ren Y, Tu YF, Shen Y, Liu F, Bao YQ, Jia WP. 2014. Retinal microvascular abnormalities are associated with early carotid atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes mellitus. *Journal of Diabetic Complications* 28:378–385 DOI 10.1016/j.jdiacomp.2014.02.004.

Liang CC, Lin PC, Lee MY, Chen SC, Shin SJ, Hsiao PJ, Lin KD, Hsu WH. 2016. Association of serum uric acid concentration with diabetic retinopathy and albuminuria in Taiwanese patients with type 2 diabetes mellitus. *International Journal of Molecular Sciences* 17:1248 DOI 10.3390/ijms17081248.

Ma Z, Zhang J, Kang X, Xu C, Sun C, Tao L, Zheng D, Han Y, Li Q, Guo X, Yang X. 2020. Hyperuricemia precedes non-alcoholic fatty liver disease with abdominal obesity moderating this unidirectional relationship: three longitudinal analyses. *Atherosclerosis* 311:44–51 DOI 10.1016/j.atherosclerosis.2020.08.006.

Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, Matsuzawa Y. 1998. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. *Metabolism: Clinical and Experimental* 47:929–933 DOI 10.1016/s0026-0495(98)90346-8.

Niu SW, Chang KT, Ta A, Chang YH, Kuo IC, Hung CC, Chiu YW, Hwang SJ, Lin SF, Lin HY. 2018. Decreased incidence of diabetes in patients with gout using benzbromarone. *Rheumatology* 57:1574–1582 DOI 10.1093/rheumatology/key138.

Peterson SB, Hart GW. 2016. New insights: a role for O-GlcNAcylation in diabetic complications. *Critical Reviews in Biochemistry and Molecular Biology* 51:150–161 DOI 10.3109/10409238.2015.1135102.

Rock KI, Kataoka H, Lai JJ. 2013. Uric acid as a danger signal in gout and its comorbidities. *Nature Reviews Rheumatology* 9:13–23 DOI 10.1038/nrrheum.2012.143.

Sabanayagam C, Foo VH, Ikram MK, Huang H, Lim SC, Lamoureux EL, Tai ES, Wong TY. 2014. Is chronic kidney disease associated with diabetic retinopathy in Asian adults? *Journal of Diabetes* 6:556–563 DOI 10.1111/1753-0407.12148.
Shabeeb D, Najafi M, Hasanzadeh G, Hadian MR, Musa AE, Shirazi A. 2018. Electrophysiological measurements of diabetic peripheral neuropathy: a systematic review. *Diabetes and Metabolic Syndrome* 12:591–600 DOI 10.1016/j.dsx.2018.03.026.

Su HY, Yang C, Liang D, Liu HF. 2020a. Research advances in the mechanisms of hyperuricemia-induced renal injury. *BioMed Research International* 2020:5817348 DOI 10.1155/2020/5817348.

Su M, Sun L, Li W, Liu H, Liu Y, Wei Y, Yuan Y, Zheng L, Yin S, Dai C, Zhao C, Pan Z, Li Y. 2020b. Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging. *Clinical Science* 134:1537–1553 DOI 10.1042/cs20200580.

Turak O, Ozcan F, Tok D, `Isleyen A, Sökmen E, Taşo¤lu I, Ay¤du¤ S, Sen N, McFann K, Johnson RJ, Kanbay M. 2013. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. *Journal of Clinical Hypertension* 15:7–13 DOI 10.1111/jch.12026.

Wang G, Ouyang J, Li S, Wang H, Lian B, Liu Z, Xie L. 2019. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. *Journal of Translational Medicine* 17:264 DOI 10.1186/s12967-019-2016-y.

Wu SJ, Zhu GQ, Ye BZ, Kong FQ, Zheng ZX, Zou H, Shi KQ, Lin L, Braddock M, Huang WJ, Chen YP, Zheng MH. 2015. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. *Medicine* 94:e802 DOI 10.1097/md.0000000000000802.

Xia Q, Zhang SH, Yang SM, Zhu XL, Su S, Hu AP, Zhu J, Li DM. 2020. Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. *Journal of the Chinese Medical Association* 83:350–356 DOI 10.1097/JCMA.000000000000285.

Xiong Q, Liu J, Xu Y. 2019. Effects of uric acid on diabetes mellitus and its chronic complications. *International Journal of Endocrinology* 2019:1–8.

Xu L, Li T, Yin J, Lin G, Xu Y, Ren Y, Wang Y, Yang J, Chen L. 2019. Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus. *PeerJ* 7:e7563 DOI 10.7717/peerj.7563.

Yamamoto M, Fujihara K, Ishizawa M, Osawa T, Kaneko M, Ishiguro H, Matsubayashi Y, Seida H, Yamanaka N, Tanaka S, Kodama S, Hasebe H, Sone H. 2019. Overt proteinuria, moderately reduced egfr and their combination are predictive of severe diabetic retinopathy or diabetic macular edema in diabetes. *Investigative Ophthalmology and Visual Science* 60:2685–2689 DOI 10.1167/iovs.19-26749.

Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. 2010. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. *Journal of Hypertension* 28:1234–1242.
Zhong X, Zhang D, Yang L, Du Y, Pan T. 2019. The relationship between serum uric acid within the normal range and β-cell function in Chinese patients with type 2 diabetes: differences by body mass index and gender. *PeerJ* 7:e6666 DOI 10.7717/peerj.6666.

Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. 2012. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. *Diabetes Care* 35:99–104 DOI 10.2337/dc11-1346.